Home » Stocks » Cara Therapeutics

Cara Therapeutics, Inc. (CARA)

Stock Price: $14.24 USD -0.05 (-0.35%)
Updated Oct 23, 2020 12:41 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 667.67M
Revenue (ttm) 24.02M
Net Income (ttm) -115.44M
Shares Out 46.89M
EPS (ttm) -2.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $14.24
Previous Close $14.29
Change ($) -0.05
Change (%) -0.35%
Day's Open 14.40
Day's Range 14.10 - 14.54
Day's Volume 164,966
52-Week Range 8.88 - 26.67

More Stats

Market Cap 667.67M
Enterprise Value 541.04M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 46.89M
Float 42.88M
EPS (basic) -2.51
EPS (diluted) -2.50
FCF / Share -2.62
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.41M
Short Ratio 10.64
Short % of Float 10.27%
Beta 1.68
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 27.79
PB Ratio 4.70
Revenue 24.02M
Operating Income -120.29M
Net Income -115.44M
Free Cash Flow -122.76M
Net Cash 126.63M
Net Cash / Share 2.70
Gross Margin -391.02%
Operating Margin -500.72%
Profit Margin -480.60%
FCF Margin -511.00%
ROA -47.25%
ROE -96.01%
ROIC -77.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$33.00*
(131.74% upside)
Low
18.0
Current: $14.24
High
40.0
Target: 33.00
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue19.8913.470.910.093.803.1811.961.19-
Revenue Growth47.64%1378.49%959.3%-97.74%19.7%-73.45%905.38%--
Gross Profit19.8913.470.910.093.803.1811.961.19-
Operating Income-112-77.38-59.49-58.40-25.19-18.07-0.24-6.24-9.75
Net Income-106-74.01-58.13-57.28-24.69-17.75-3.96-6.27-9.81
Shares Outstanding42.6735.8931.2027.2824.6220.974.133.303.24
Earnings Per Share-2.49-2.06-1.86-2.10-1.00-0.85-0.74-1.90-3.03
Operating Cash Flow-109-22.30-54.83-47.38-21.48-17.642.83-6.03-6.85
Capital Expenditures-0.02-0.07-0.02-0.72-0.02-0.04-0.010.510.05
Free Cash Flow-109-22.37-54.84-48.10-21.50-17.682.82-5.52-6.80
Cash & Equivalents15516293.3459.7510753.3613.061.825.09
Total Debt4.32------0.780.75
Net Cash / Debt15116293.3459.7510753.3613.061.044.34
Assets23319197.0063.8311155.9318.085.5410.69
Liabilities46.2557.1910.2213.105.854.2772.1663.6762.75
Book Value18713486.7850.7310551.66-54.08-58.13-52.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cara Therapeutics, Inc.
Country United States
Employees 72
CEO Derek T. Chalmers

Stock Information

Ticker Symbol CARA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CARA
IPO Date January 31, 2014

Description

Cara Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.